Answers are grounded in this paper and cite their sources.
Long-term efficacy of nivolumab was confirmed at the 3-year follow-up, and a survival benefit of TBP with nivolumab was suggested. Biomarkers for selecting patients suitable for TBP with nivolumab should be identified in the future.
No takes yet. Share an insight, caveat, or question.
Boku et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: